Avanos Medical director equity cashed out at $25
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Avanos Medical, Inc. director Patrick J. O’Leary reported the disposition to the issuer of 54,640 shares of common stock and 12,003 restricted share units on July 27, 2026. In connection with a completed merger, each share and unit was converted into the right to receive $25.00 in cash, leaving him with no reported direct holdings.
Insider Trade Summary
Disposition: 66,643 shares
Disposition
2 txns
Insider
OLEARY PATRICK J
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Restricted Share Units F2, F3 | 12,003 | $25.00 | $300K |
| Disposition | Common Stock F1 | 54,640 | $25.00 | $1.37M |
Holdings After Transaction:
Restricted Share Units — 0 units (Direct);
Common Stock — 0 shares (Direct)
Footnotes (3)
- F1. Pursuant to the Agreement and Plan of Merger, dated as of April 13, 2026 (as it has been or may be amended, supplemented, waived or otherwise modified in accordance with its terms, the Merger Agreement), by and among the Issuer, A-AV Holdco I, Inc., a Delaware corporation, and A-AV MergerSub, Inc. (Parent), a Delaware corporation and a wholly-owned subsidiary of Parent, each share of the Issuer's common stock, par value $0.01 per share, that was issued and outstanding immediately prior to the effective time of the merger (the Merger), which occurred on July 27, 2026, was converted into and exchanged for the right to receive $25.00 per share in cash, without interest (the Merger Consideration), payable in accordance with the terms and subject to the conditions of the Merger Agreement.
- F2. Represents restricted share units issued to the Reporting Person on May 8, 2026. Each restricted share unit represents a contingent right to receive a cash payment equal to the value of one share of the Issuer's common stock.
- F3. Pursuant to the Merger Agreement, these cash-settled restricted share units were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying: (i) the Merger Consideration by (ii) the number of shares of Common Stock subject to the restricted share unit award (less applicable tax withholdings).
Key Figures
Common shares disposed: 54,640 shares
Restricted share units canceled: 12,003 units
Merger Consideration: $25.00 per share
+4 more
7 metrics
Common shares disposed
54,640 shares
Disposition to issuer in merger on July 27, 2026
Restricted share units canceled
12,003 units
Cash-settled RSUs converted to cash rights at merger
Merger Consideration
$25.00 per share
Cash paid for each issued and outstanding common share at merger
Holdings after transaction
0.0000 shares
Direct common stock position following July 27, 2026 disposition
Merger agreement date
April 13, 2026
Date of Agreement and Plan of Merger
Merger effective date
July 27, 2026
Date the merger occurred and consideration became payable
RSU grant date
May 8, 2026
Date the reported restricted share units were issued to O’Leary
Key Terms
Agreement and Plan of Merger, Merger Consideration, Effective Time of the Merger, restricted share units, +1 more
5 terms
Agreement and Plan of Merger regulatory
"Pursuant to the Agreement and Plan of Merger, dated as of April 13, 2026"
An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.
Merger Consideration financial
"right to receive $25.00 per share in cash, without interest (the Merger Consideration)"
Merger consideration is the total payment a company or buyer offers to shareholders of a target company in exchange for combining the two businesses, and can include cash, shares in the surviving company, debt assumption, or a mix of these. Investors care because the form and amount affect the deal’s value, tax consequences, immediate cash received versus future ownership, and the risk and upside of holding new shares — similar to choosing between cash now or stock that could grow later.
Effective Time of the Merger regulatory
"canceled immediately prior to the Effective Time of the Merger and converted"
The effective time of the merger is the exact moment when a planned combination of two companies legally takes effect, usually specified in the merger agreement and reflected by the formal filing or timestamp. For investors, it is the point when ownership, voting rights, financial reporting and control shift—like a light switch flipping that joins two rooms into one—so it determines when shares convert, who controls corporate decisions and which results appear in financial statements.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did AVNS director Patrick J. O’Leary report?
Patrick J. O’Leary reported disposing of 54,640 common shares and 12,003 restricted share units on July 27, 2026. These equity interests were converted into cash rights as part of a merger at $25.00 per share or unit.
Was Patrick J. O’Leary’s AVNS transaction under a Rule 10b5-1 plan?
The filing’s Rule 10b5-1 checkbox is not marked, and no footnote describes a trading plan. The transactions are characterized as dispositions to the issuer arising from the terms of the merger agreement.
What merger affected Patrick J. O’Leary’s AVNS holdings?
An Agreement and Plan of Merger dated April 13, 2026 between Avanos Medical, A-AV Holdco I, Inc., and A-AV MergerSub, Inc. closed on July 27, 2026, converting each outstanding common share into the right to receive $25.00 in cash.
AI-generated analysis. How Rhea-AI works. Not financial advice.
